Zhou Kehui, Li Chaoqun, Shi Wen, Hu Xiaodan, Nandakumar Kutty Selva, Jiang Shibo, Zhang Naru
Department of Clinical Medicine, School of Medicine, Zhejiang University City College, Hangzhou 310015, China.
School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Vaccines (Basel). 2021 Sep 9;9(9):1004. doi: 10.3390/vaccines9091004.
Zika virus (ZIKV) is an arbovirus first discovered in the Americas. ZIKV infection is insidious based on its mild clinical symptoms observed after infection. In Brazil, after 2015, ZIKV infection broke out on a large scale, and many infected pregnant women gave birth to babies with microcephaly. The teratogenic effects of the virus on the fetus and its effects on nerves and the immune system have attracted great attention. Currently, no specific prophylactics or therapeutics are clinically available to treat ZIKV infection. Development of a safe and effective vaccine is essential to prevent the rise of any potential pandemic. In this review, we summarize the latest research on Zika vaccine development based on different strategies, including DNA vaccines, subunit vaccines, live-attenuated vaccines, virus-vector-based vaccines, inactivated vaccines, virus-like particles (VLPs), mRNA-based vaccines, and others. We anticipate that this review will facilitate further progress toward the development of effective and safe vaccines against ZIKV infection.
寨卡病毒（ZIKV）是一种虫媒病毒，最初在美洲被发现。基于感染后观察到的轻微临床症状，寨卡病毒感染具有隐匿性。2015年后，寨卡病毒感染在巴西大规模爆发，许多感染的孕妇产下了患有小头畸形的婴儿。该病毒对胎儿的致畸作用及其对神经和免疫系统的影响引起了极大关注。目前，临床上尚无治疗寨卡病毒感染的特异性预防或治疗方法。开发安全有效的疫苗对于预防任何潜在大流行的爆发至关重要。在本综述中，我们总结了基于不同策略的寨卡疫苗开发的最新研究，包括DNA疫苗、亚单位疫苗、减毒活疫苗、病毒载体疫苗、灭活疫苗、病毒样颗粒（VLP）、mRNA疫苗等。我们预计，本综述将促进针对寨卡病毒感染开发有效且安全疫苗的进一步进展。
